Ovarian adenocarcinoma
Information
- Disease name
- Ovarian adenocarcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT05451849 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | June 21, 2022 | October 30, 2028 |
| NCT03365791 | Completed | Phase 2 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | January 24, 2018 | September 17, 2020 |
| NCT02217956 | Completed | Phase 1 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma | June 2011 | June 2015 |
| NCT04248231 | Completed | CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma | September 15, 2019 | December 23, 2021 | |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT03641287 | Terminated | N/A | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | December 5, 2018 | September 30, 2022 |
| NCT02923739 | Terminated | Phase 2 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 5, 2017 | September 27, 2022 |
| NCT00899093 | Terminated | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy | September 2007 |